Clinical TrialsSearch results
Number of results: 701
Other
- A multicenter phase II study of FOLFIRI as first-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with homozygous for UGT1A1(FLIGHT1)
- colorectal cancer
- NPO Epidemiological and Clinical Research Information Network
- 2009-09-01
Other
- A multicenter phaseII study of FOLFIRI as FOLFOX refractory second-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with honozygous for UGT1A1: (FLIGHT2)
- colorectal cancer
- NPO Epidemiological and Clinical Research Information Network
- 2009-09-10
Not yet recruiting
- Phase I Clinical Trial of KK2845 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- relapsed or refractory acute myeloid leukemia
- Noshiro Masayoshi
- 2024-04-21
Other
- Phase II study of irinotecan and tegafur gimeracil for NSCLC with EGFR mutation which resistant to EGFR-TKI
- Non-small-cell lung cancer
- North Japan Lung Cancer Study Group
- 2010-08-31
Other
- A Phase 3, Double-Blind, Placebo-Controlled Study of NPC-06 in Patients with Trigeminal neuralgia
- Trigeminal neuralgia
- Noro Shusaku
- 2023-03-03
Recruiting
- A Study of TAK-341 in Treatment of Multiple System Atrophy
- Multiple System Atrophy
- Nonomura Hidenori
- 2022-12-20
Other
- The changes of QOL in patients with Alzherimer's disease through medical treatment: an observational study
- Alzheimer's disease
- Non Profit Organization Institute of Community Medicine and Welfare for Central Nervous System
- 2008-07-19
Other
- Study for the effects of imeglimin on glycemic control in patients with type 2 diabetes
- type 2 diabetes
- Nomoto Hiroshi
- 2022-05-11
Other
- Study for the effects of semaglutid on glycemic control and quality of life in patients with type 2 diabetes
- type 2 diabetes
- Nomoto Hiroshi
- 2020-11-06
Completed
- Study for the effects of once-daily semaglutid on glycemic control in patients with type 2 diabetes (SWITCH SEMA-2 study)
- type 2 diabetes
- Nomoto Hiroshi
- 2021-08-26